Luz Ibarra-Lara Selected Research

Myocardial Infarction

1/2020	Nonclassical Axis of the Renin-Angiotensin System and Neprilysin: Key Mediators That Underlie the Cardioprotective Effect of PPAR-Alpha Activation during Myocardial Ischemia in a Metabolic Syndrome Model.
1/2019	Clofibrate Treatment Decreases Inflammation and Reverses Myocardial Infarction-Induced Remodelation in a Rodent Experimental Model.
11/2017	Extracts of Crataegus oxyacantha and Rosmarinus officinalis Attenuate Ischemic Myocardial Damage by Decreasing Oxidative Stress and Regulating the Production of Cardiac Vasoactive Agents.
12/2016	Fenofibrate Therapy Restores Antioxidant Protection and Improves Myocardial Insulin Resistance in a Rat Model of Metabolic Syndrome and Myocardial Ischemia: The Role of Angiotensin II.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Luz Ibarra-Lara Research Topics

Disease

4	Inflammation (Inflammations) 03/2023 - 10/2012
4	Myocardial Infarction 01/2020 - 12/2016
4	Myocardial Ischemia (Ischemic Heart Diseases) 01/2020 - 10/2012
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 03/2023 - 12/2016
3	Ischemia 01/2020 - 05/2015
3	Hypertension (High Blood Pressure) 01/2019 - 02/2010
3	Aortic Coarctation 01/2019 - 02/2010
1	Fibrosis (Cirrhosis) 03/2023
1	Heart Failure 03/2023
1	Reperfusion Injury 03/2023
1	Kidney Diseases (Kidney Disease) 10/2022
1	Hypoxia (Hypoxemia) 01/2021
1	Ventricular Remodeling 01/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2016
1	Insulin Resistance 12/2016

Drug/Important Bio-Agent (IBA)

7	salicylhydroxamic acid (SHAM)IBA 01/2020 - 10/2012
5	Clofibrate FDA Link 03/2023 - 10/2012
4	PPAR alphaIBA 03/2023 - 02/2010
4	AntioxidantsIBA 10/2022 - 02/2010
4	Angiotensin IIIBA 01/2020 - 02/2010
3	Fenofibrate (CiL)FDA LinkGeneric 01/2021 - 12/2016
3	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2020 - 05/2015
2	angiotensin I (1-7)IBA 01/2020 - 01/2019
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 08/2016 - 10/2012
1	Biomarkers (Surrogate Marker)IBA 03/2023
1	Atrial Natriuretic Factor (ANF)IBA 03/2023
1	Metalloproteases (Metalloproteinases)IBA 03/2023
1	PhytochemicalsIBA 10/2022
1	Environmental Pollutants (Pollutants, Environmental)IBA 10/2022
1	Ellagic AcidIBA 10/2022
1	Glucose (Dextrose)FDA LinkGeneric 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	Angiotensin IIIIBA 01/2020
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2020
1	Neprilysin (Neutral Endopeptidase)IBA 01/2020
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2020
1	des-Asp(1)-des-Arg(2)-Ile(5)- angiotensin IIIBA 01/2020
1	Triglycerides (Triacylglycerol)IBA 12/2016
1	HDL CholesterolIBA 12/2016
1	Fibric Acids (Fibrates)IBA 12/2016
1	Type 1 Angiotensin ReceptorIBA 12/2016
1	Insulin (Novolin)FDA Link 12/2016
1	Vasodilator Agents (Vasodilators)IBA 12/2016
1	Captopril (Capoten)FDA LinkGeneric 08/2016

Therapy/Procedure

1	Therapeutics 12/2016